OncLive Staff

Articles

FDA Approval Insights: Toripalimab in Recurrent/Metastatic Nasopharyngeal Carcinoma

December 4th 2023

Drs Hanna and Kandula discuss the significance of the FDA approval of toripalimab in nasopharyngeal carcinoma; pivotal data from the JUPITER-02 and POLARIS-02 trials; and how this regulatory decision increases the importance of multidisciplinary collaboration.

Lunning and Jacobson Dissect the Role of CAR T-Cell Therapy in Follicular Lymphoma

November 30th 2023

Drs Lunning and Jacobson discuss the characteristics of follicular lymphoma that may prompt aggressive treatment, the potential optimal role of CAR T-cell therapy in the third line and beyond, and how the toxicity profiles of different CAR T-cell products compare with each other.

Camidge and McVeigh Highlight the Role of the Clinical Geneticist Across Cancer Care and Research

November 27th 2023

Drs Camidge and McVeigh highlight the evolution of the clinical genetics field over time, the process of identifying pathogenic genetic variants, the difficulties of explaining genetic testing results to patients, and more.

Dumbrava Details Ongoing Research With PC14586 in p53 Y220C–Mutated Advanced Solid Tumors

November 23rd 2023

Dr Dumbrava discusses the rationale and design of the PYNNACLE trial; phase 1 efficacy and safety findings with PC14586 in patients with p53 Y220C–mutated advanced solid tumors; and the next steps for this research.

FDA Approval Insights: Ivosidenib in R/R IDH1+ Myelodysplastic Syndrome

November 20th 2023

Dr DiNardo discusses the the FDA approval of ivosidenib for patients with relapsed/refractory IDH1-mutant myelodysplastic syndromes, the unique mechanism of action of ivosidenib, and key efficacy and safety findings from the AG120-C-001 trial.

Halmos Highlights Evaluation of the EGFR Inhibitor BDTX-1535 in NSCLC

November 16th 2023

Dr Halmos discusses the ongoing investigation of the potent, selective, and irreversible EGFR inhibitor BDTX-1535 in patients with non–small cell lung cancer.

Feigin Discusses the Association Between Benzodiazepines and Pancreatic Cancer Outcomes

November 13th 2023

Dr Feigin discusses findings from a study on the varying effects of the benzodiazepines lorazepam and alprazolam on progression-free survival outcomes for patients with pancreatic cancer.

Khouri Highlights the Ongoing AFFIRM-AL Trial in AL Amyloidosis

November 9th 2023

Dr Khouri discusses unmet needs in AL amyloidosis, the potential for birtamimab to become a new frontline standard of care, and the importance of confirming earlier post-hoc results from the VITAL trial in the AFFIRM-AL trial in patients with Mayo stage IV AL amyloidosis with cardiac involvement.

FDA Approval Insights: Adjuvant Nivolumab in Completely Resected Stage IIB/C Melanoma

November 6th 2023

Dr Weber discusses the FDA approval of adjuvant nivolumab for patients with completely resected stage IIB/C melanoma, key efficacy data from the CheckMate76K trial, and potential future directions for PD-1 inhibitor–based combinations in the melanoma treatment paradigm.

Camidge and Garon Unpack Key Updates From the 2023 IASLC World Conference on Lung Cancer

November 2nd 2023

In this episode of How This Is Building Me, Drs Camidge and Garon discuss the differences in lung cancer management and drug advancement between the United States and Asia and highlight other topline takeaways from the 2023 WCLC.

Lunning and Nastoupil Highlight Treatment Considerations and Ongoing Research in Follicular Lymphoma

October 30th 2023

Drs Lunning and Nastoupil discuss the ins and outs of diagnostic workups for patients with follicular lymphoma; how to discern which patients may benefit most from standard chemotherapy vs clinical trial regimens in the frontline setting; and ongoing follicular lymphoma research that may alter the treatment paradigm.

Naumann Discusses Notable Research Efforts in Endometrial Cancer

October 26th 2023

Dr Naumann discusses the role of frontline maintenance therapy for patients with endometrial cancer; which patients are likely to benefit from the RUBY and NRG-GY018 trial regimens; and ongoing research that may elucidate optimal treatments for patients with recurrent, mismatch repair–deficient disease.

Keshava Emphasizes the Importance of Lung Nodule Programs for Early Lung Cancer Detection

October 23rd 2023

Dr Keshava discusses the rationale behind lung nodule programs, common barriers to implementing these programs, and how multidisciplinary collaboration can lead to successful early lung cancer diagnoses.

Hasanuma Highlights the Benefits of Building Authentic Connections Through Mentorship

October 19th 2023

Dr Hasunuma shares that the objective of mentorship is to foster care, trust, and respect in mentor-mentee relationships and create authentic connections.

FDA Approval Insights: Momelotinib in Myelofibrosis With Anemia

October 16th 2023

Dr Kuykendall discusses the FDA approval of momelotinib in myelofibrosis with anemia, key data from the MOMENTUM trial, and how momelotinib alters the myelofibrosis treatment paradigm.

New Data Bring Excitement, Raise Questions in Advanced RCC

October 16th 2023

Although renal cell carcinoma remains a difficult-to-treat disease, with patients with clear cell histology experiencing a median overall survival of approximately 13 months and a 5-year overall survival rate of less than 10%, updated results from clinical trials examining emerging therapeutic strategies have spurred optimism.

Gutierrez and Leslie Discuss Recent Efforts and Future Advances in CAR T-Cell Therapy

October 12th 2023

Drs Gutierrez and Leslie discuss common barriers that institutions face when implementing CAR T-cell therapy programs, the early success story of outpatient administration of this modality at John Theurer Cancer Center, and future considerations for using this treatment approach in solid tumors.

Expert Insights on the United States Chemotherapy Shortage

October 9th 2023

Oncology experts discuss the platinum chemotherapy shortage in the United States.

FDA Approval Insights: First-Line Luspatercept for Anemia in Lower-Risk MDS

October 5th 2023

Dr Platzbecker discusses the FDA approval of luspatercept in lower-risk myelodysplastic syndrome with anemia; key efficacy and safety data from the COMMANDS trial; and how this approval addresses historically unmet needs for this population.

Richardson Reviews Findings and Future Directions With Mezigdomide Plus Dexamethasone in R/R Myeloma

October 2nd 2023

Dr Richardson discusses the background of mezigdomide, key efficacy and safety findings with the agent plus dexamethasone in patients with relapsed/refractory multiple myeloma, and the implications of this combination for heavily pretreated patients in this population.